Example: Heart Attack
Clinical Trials Sponsored by Sunesis Pharmaceuticals
Total 17 results
-
NCT03037645TerminatedConditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Mantle-Cell Lymphoma; Waldenstrom Macroglobulinemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma
-
NCT01191801CompletedConditions: Acute Myeloid Leukemia
-
NCT00607997CompletedConditions: Leukemia; Acute Disease; Acute Myeloid Leukemia; Nonlymphocytic Leukemia; Myelodysplastic Syndromes
-
NCT00541866CompletedConditions: Acute Myeloid Leukemia
-
NCT00519662CompletedConditions: Advanced Solid Tumors
-
NCT00446342CompletedConditions: B-lymphoid Malignancies; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Multiple Myeloma
-
NCT00408603CompletedConditions: Epithelial Ovarian Cancer
-
NCT00298896CompletedConditions: Carcinoma, Small Cell; Small Cell Lung Cancer
-
NCT00292864CompletedSafety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid TumorsConditions: Tumors
-
NCT00252382CompletedConditions: Carcinoma, Non-Small-Cell Lung
-
NCT00246662CompletedConditions: Leukemia, Lymphocytic, Acute; Leukemia, Nonlymphocytic, Acute; Leukemia, Myeloid, Chronic; Myelodysplastic Syndromes
-
NCT00094159CompletedConditions: Neoplasms
-
NCT00091585CompletedConditions: Neoplasms
-
NCT03338348CompletedConditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
-
NCT01913951Active, not recruitingConditions: Myelodysplastic Syndromes
-
NCT01980056CompletedVosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based TherapyConditions: Myelodysplastic Syndrome
-
NCT01893320CompletedConditions: Leukemia